BPBethany Lee Patenall

Bethany Lee Patenall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bethany Lee Patenall has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rational design and in vitro testing of new urease inhibitors to prevent urinary catheter blockage

    by Rachel A. Heylen, Nicola Cusick, Tom White, Emily J. Owen, Bethany L. Patenall, Martin Alm, Peter Thomsen, Maisem Laabei, A. Toby A. Jenkins

    In silico identification of urease inhibitors based on thiourea, tested to determine IC 50 and tested on a catheterised in vitro bladder model, showing efficacy in reducing catheter blockage.


  • Open Access

    Rational design and in vitro testing of new urease inhibitors to prevent urinary catheter blockage

    by Rachel A. Heylen, Nicola Cusick, Tom White, Emily J. Owen, Bethany L. Patenall, Martin Alm, Peter Thomsen, Maisem Laabei, A. Toby A. Jenkins

    In silico identification of urease inhibitors based on thiourea, tested to determine IC50 and tested on a catheterised in vitro bladder model, showing efficacy in reducing catheter blockage.

  • Open Access

    Kick-Starting Wound Healing: A Review of Pro-Healing Drugs

    by Bethany L. Patenall, Kristyn A. Carter, Matthew R. Ramsey

    Cutaneous wound healing consists of four stages: hemostasis, inflammation, proliferation/repair, and remodeling. While healthy wounds normally heal in four to six weeks, a variety of underlying medical conditions can impair the progression through the stages of wound healing, resulting in the development of chronic, non-healing wounds. Great progress has been made in developing wound dressings and improving surgical techniques, yet challenges remain in finding effective therapeutics that directly promote healing. This review examines the current understanding of the pro-healing effects of targeted pharmaceuticals, re-purposed drugs, natural products, and cell-based therapies on the various cell types present in normal and chronic wounds. Overall, despite several promising studies, there remains only one therapeutic approved by the United States Food and Drug Administration (FDA), Becaplermin, shown to significantly improve wound closure in the clinic. This highlights the need for new approaches aimed at understanding and targeting the underlying mechanisms impeding wound closure and moving the field from the management of chronic wounds towards resolving wounds.


  • Open Access

    PRMT1 Inhibition Selectively Targets BNC1-Dependent Proliferation, but not Migration in Squamous Cell Carcinoma

    by Rafik Boudra, Bethany L. Patenall, Sandra King, Diana Wang, Sarah A. Best, Joo Yeon Ko, Shuyun Xu, Maria G. Padilla, Chrysalyne D. Schmults, Steven R. Barthel, et al.

    Summary: Squamous Cell Carcinoma (SCC) develops in stratified epithelial tissues and demonstrates frequent alterations in transcriptional regulators. We sought to discover SCC-specific transcriptional programs and identified the transcription factor Basonuclin 1 (BNC1) as highly expressed in SCC compared to other tumor types. RNA-seq and ChIP-seq analysis identified pro-proliferative genes activated by BNC1 in SCC cells and keratinocytes. Inhibition of BNC1 in SCC cells suppressed proliferation and increased migration via FRA1. In contrast, BNC1 reduction in keratinocytes caused differentiation, which was abrogated by IRF6 knockdown, leading to increased migration. Protein interactome analysis identified PRMT1 as a co-activator of BNC1-dependent proliferative genes. Inhibition of PRMT1 resulted in a dose-dependent reduction in SCC cell proliferation without increasing migration. Importantly, therapeutic inhibition of PRMT1 in SCC xenografts significantly reduced tumor size, resembling functional effects of BNC1 knockdown. Together, we identify BNC1-PRMT1 as an SCC-lineage specific transcriptional axis that promotes cancer growth, which can be therapeutically targeted to inhibit SCC tumorigenesis. Abstract Figure:

  • Open Access

    TCF-based fluorescent probe for monitoring superoxide anion produced in bacteria under chloramphenicol- and heat-induced stress

    by Kai-Cheng Yan, Bethany L. Patenall, Jordan E. Gardiner, Rachel A. Heylen, Naing Thet, Xiao-Peng He, Adam C. Sedgwick, Tony D. James, A. Toby A. Jenkins

    We report on a superoxide anion (O 2 ˙ − ) responsive fluorescent probe called TCF-OTf.


  • Open Access

    Pilot Clinical Trial to test the function of a Diagnostic Sensor in predicting Impending Urinary Catheter Blockage in Long-term Catheterized Patients

    by Rachel A. Heylen, June Mercer-Chalmers, Annette Morton, James Urie, Edward Jefferies, Bethany L. Patenall, Maisem Laabei, A. Toby. A. Jenkins

    Trial design: Pilot feasibility trial. Methods: Participants: adults attending the Outpatient Urology Clinic, having a long-term indwelling urinary catheter and have the mental capacity to consent. Consent for the donation of the urinary catheter and drainage bag were gained at the Urology Clinic, Royal United Hospital (RUH) Bath, alongside a quality-of-life questionnaire. Interventions: there was no direct intervention to the participants, the trial was to test the functionality of the diagnostic sensor, there was no change to the participant’s medical care. Objectives: recruitment of 48 participants to donate catheter and drainage bags (including re-recruits); assess the functionality of the sensor to predict impending catheter blockage in human urine; assess the functionality to release at pH > 7; and assess the microbiological profile of the patients with long-term catheters. Outcome: determination of whether the participant had a blockage event 3 weeks post catheter change, and whether this matched with the result from the sensor. Measurements of the participant’s urine to assess whether the sensor could detect human urine at a pH > 7. Determine the microbial species present in the drainage bag of the participants. Results: Recruitment: received 35 samples from 28 individuals. Outcome: two participants reported blockage events which were successfully detected by the sensor. However, the sensor also predicted blockage in participants that did not block within the 3-week report time period, sensitivity = 100%, specificity = 58.06%. The functionality of the sensor to detect urine above pH > 7 had a sensitivity = 78.75% and a specificity = 96.77%, which gave a p = 2.06×10 −24 (χ 2 test). Inclusion of the maintenance solution prescribed to participants, to test the predictability of the sensor, gave a sensitivity = 100%, and a specificity = 62.95%, p = 0.029 (Fisher Exact test). Microbiological analysis indicated that Proteus spp. and Pseudomonas spp. were the most commonly isolated microbes. Harm: No adverse events. Conclusions: The sensor can predict participants more prone to catheter blockage, and it is accurate in detecting urine with a pH >7. Owing to the small sample number of this trial, the results are not statistically powered. However, the data can be used to improve the design of the sensor and inform the design of a larger, randomized clinical trial. Trial registration: Trial was ethically approved by the Research Ethics Committee (REC) number: 20/LO/0094. Integrated Research Application System (IRAS) number: 261095. Funding: trial was funded by the Urology Foundation and an IAA seed grant, University of Bath.


  • Optimisation of a lozenge-based sensor for detecting impending blockage of urinary catheters

    by Rachel A. Heylen, Max Branson, Lauren Gwynne, Bethany L. Patenall, Nina Hauschildt, James Urie, June Mercer-Chalmers, Naing T. Thet, Maisem Laabei, A. Toby A. Jenkins


  • Open Access

    TCF-ALP: a fluorescent probe for the selective detection of Staphylococcus bacteria and application in “smart” wound dressings

    by Lauren Gwynne, George T. Williams, Kai-Cheng Yan, Bethany L. Patenall, Jordan E. Gardiner, Xiao-Peng He, Jean-Yves Maillard, Tony D. James, Adam. C. Sedgwick, A. Toby. A. Jenkins

    Alkaline phosphatase (ALP) is an important enzyme-based biomarker present in several bacterial species; however, it is currently undervalued as a strategy to detect pathogenic bacteria. Here, we explore our ALP-responsive colorimetric and fluorescent probe (TCF-ALP) for such applications. TCF-ALP displayed a colorimetric and fluorescence response towards Staphylococcus aureus (S. aureus), with a limit of detection of 3.7 × 106 CFU mL−1 after 24 h incubation. To our surprise, TCF-ALP proved selective towards Staphylococcus bacteria when compared with Enterococcus faecalis (E. faecalis), and Gram-negative P. aeruginosa and E. coli. Selectivity was also seen in clinically relevant S. aureus biofilms. Owing to the high prevalence and surface location of S. aureus in chronic wounds, TCF-ALP was subsequently encapsulated in polyvinyl alcohol (PVA)-based hydrogels as a proof-of-concept “smart” wound dressing. TCF-ALP hydrogels were capable of detecting S. aureus in planktonic and biofilm assays, and displayed a clear colour change from yellow to purple after 24 h incubation using ex vivo porcine skin models. Overall, TCF-ALP is a simple tool that requires no prior knowledge, training, or specialist equipment, and has the potential to overcome issues related to invasive swabbing and tissue biopsy methods. Thus, TCF-ALP could be used as a tool to monitor the early development of infection in a wound and allow for the rapid provision of appropriate treatment for Staphylococcal bacterial infections.


  • Open Access

    Reaction-based indicator displacement assay (RIA) for the development of a triggered release system capable of biofilm inhibition

    by Bethany L. Patenall, George T. Williams, Lauren Gwynne, Liam J. Stephens, Emma V. Lampard, Hollie J. Hathaway, Naing T. Thet, Amber E. Young, Mark J. Sutton, Robert D. Short, et al.

    Here, a reaction-based indicator displacement hydrogel assay (RIA) was developed for the detection of hydrogen peroxide (H 2 O 2 ) via the oxidative release of the optical reporter Alizarin Red S (ARS).


  • Delivery and quantification of hydrogen peroxide generated via cold atmospheric pressure plasma through biological material

    by H J Hathaway, B L Patenall, N T Thet, A C Sedgwick, G T Williams, A T A Jenkins, S L Allinson, R D Short

    The ability of plasma-generated hydrogen peroxide (H 2 O 2 ) to traverse bacterial biofilms and the subsequent fate of the generated H 2 O 2 has been investigated. An in vitro model, comprising a nanoporous membrane impregnated with artificial wound fluid and biofilms of varying maturity was treated with a helium-driven, cold atmospheric pressure plasma (CAP) jet. The concentration of H 2 O 2 generated below the biofilms was quantified. The results showed that the plasma-generated H 2 O 2 interacted significantly with the biofilm, thus exhibiting a reduction in concentration across the underlying nanoporous membrane. Biofilm maturity exhibited a significant effect on the penetration depth of H 2 O 2 , suggesting that well established, multilayer biofilms are likely to offer a shielding effect with respect to cells located in the lower layers of the biofilm, thus rendering them less susceptible to plasma disinfection. This may prove clinically significant in the plasma treatment of chronic, deep tissue infections such as diabetic and venous leg ulcers. Our results are discussed in the context of plasma-biofilm interactions, with respect to the fate of the longer lived reactive species generated by CAP, such as H 2 O 2 .